Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
05
04
2019
accepted:
11
09
2019
pubmed:
14
9
2019
medline:
28
4
2021
entrez:
14
9
2019
Statut:
ppublish
Résumé
Obesity correlates with hematologic malignancies including leukemias, but risk of specific leukemia subtypes like acute promyelocytic leukemia and underlying molecular mechanisms are poorly understood. We explored multiple datasets for correlation between leukemia, body mass index (BMI) and molecular features. In a population-based study (n=5.2 million), we correlated BMI with promyelocytic leukemia, and other acute myeloid, lymphoid or other leukemias. In cross-sectional studies, we tested BMI deviation in promyelocytic leukemia trial cohorts from that expected based on national surveys. We explored The Cancer Genome Atlas for transcriptional signatures and mutations enriched in promyelocytic leukemia and/or obesity, and confirmed a correlation between body mass and FLT3 mutations in promyelocytic leukemia cohorts by logistic regression. In the population-based study, hazard ratio per 5 kg/m
Identifiants
pubmed: 31515354
pii: haematol.2019.223925
doi: 10.3324/haematol.2019.223925
pmc: PMC7271575
doi:
Substances chimiques
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1559-1566Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA101937
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056341
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197561
Pays : United States
Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
PLoS One. 2014 Jun 05;9(6):e98647
pubmed: 24901309
Regul Toxicol Pharmacol. 2009 Dec;55(3):340-52
pubmed: 19703505
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Sci Rep. 2017 Dec 21;7(1):17998
pubmed: 29269861
Am J Hematol. 2016 Feb;91(2):199-204
pubmed: 26526191
Blood. 2011 May 5;117(18):4716-25
pubmed: 21385856
Blood. 2008 Feb 1;111(3):1078-84
pubmed: 17975017
Blood. 2010 Oct 28;116(17):3171-9
pubmed: 20644121
Eur J Cancer Prev. 2006 Aug;15(4):367-70
pubmed: 16835508
Proc Natl Acad Sci U S A. 1981 Jun;78(6):3887-91
pubmed: 6267608
JAMA. 2012 Feb 1;307(5):491-7
pubmed: 22253363
Nat Rev Cancer. 2012 Feb 09;12(3):181-95
pubmed: 22318237
Cell Death Dis. 2015 Dec 31;6:e2037
pubmed: 26720346
Leukemia. 1997 Oct;11(10):1661-4
pubmed: 9324286
Nucleic Acids Res. 2013 Oct;41(18):e170
pubmed: 23921631
Blood. 2012 Jan 5;119(1):49-54
pubmed: 22049518
Cancer Causes Control. 2013 Mar;24(3):427-38
pubmed: 23288400
Semin Hematol. 2014 Oct;51(4):259-72
pubmed: 25311739
Cell. 1995 Dec 1;83(5):813-9
pubmed: 8521498
Obes Surg. 2012 Jun;22(6):935-44
pubmed: 22460550
Nat Commun. 2017 Sep 19;8(1):593
pubmed: 28928446
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Sci Rep. 2018 Apr 3;8(1):5534
pubmed: 29615816
Int J Hematol. 2015 Nov;102(5):513-22
pubmed: 26440972
Annu Rev Med. 2016;67:59-72
pubmed: 26473413
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
Nat Methods. 2013 Nov;10(11):1081-2
pubmed: 24037244
Blood Cancer J. 2015 Apr 17;5:e304
pubmed: 25885425